Insulet Corp (PODD)
177.19
+1.24
(+0.70%)
USD |
NASDAQ |
May 31, 16:00
177.24
+0.05
(+0.03%)
After-Hours: 20:00
Insulet Research and Development Expense (Annual): 205.00M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 205.00M |
| December 31, 2022 | 180.20M |
| December 31, 2021 | 160.10M |
| December 31, 2020 | 146.80M |
| December 31, 2019 | 132.30M |
| December 31, 2018 | 94.80M |
| December 31, 2017 | 75.70M |
| December 31, 2016 | 55.71M |
| December 31, 2015 | 43.21M |
| December 31, 2014 | 27.90M |
| December 31, 2013 | 21.76M |
| Date | Value |
|---|---|
| December 31, 2012 | 24.36M |
| December 31, 2011 | 21.86M |
| December 31, 2010 | 16.57M |
| December 31, 2009 | 13.23M |
| December 31, 2008 | 13.10M |
| December 31, 2007 | 10.39M |
| December 31, 2006 | 8.094M |
| December 31, 2005 | 10.76M |
| December 31, 2004 | 9.026M |
| December 31, 2003 | 8.659M |
| December 31, 2002 | 9.458M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
132.30M
Minimum
2019
205.00M
Maximum
2023
164.88M
Average
160.10M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Tandem Diabetes Care Inc | 169.67M |
| Abbott Laboratories | 2.741B |
| Integra Lifesciences Holdings Corp | 104.19M |
| OraSure Technologies Inc | 33.73M |
| Stryker Corp | 1.388B |